Literature DB >> 27508050

Differential expression of miR-21 and miR-75 in esophageal carcinoma patients and its clinical implication.

Hongbo Lv1, Zhanao He1, Hongjiang Wang1, Tongxin Du1, Zuoliang Pang2.   

Abstract

In Xinjiang, China, esophageal carcinoma has a high incidence in Kazak and Uighur populations. MicroRNA (miR)-21 and miR-375 are related to esophageal carcinoma. This study thus investigated their potencials in early diagnosis and prognosis in Kazak and Uighur populations, to provide evidences for serum markers of esophageal cancer. A total of 126 Kazak or Uighur esophageal cancer patients were enrolled as the disease group, along with 86 local Han patients as disease control cohort, and 80 healthy Kazak or Uighur individuals. MiRNA expression was detected by in situ hybridization in tissues and by qRT-PCR in serum. ROC approach was used to evaluate the diagnostic value of miRNA on esophageal carcinoma. Cox analysis was performed to screen factors governing prognosis. MiR-21 level was significantly elevated in both tissue and serum samples of esophageal cancer patients, while miR-375 was down-regulated. Such difference was more potent in disease group compared to disease control group. MiR expression was correlated with infiltration depth, TNM stage, vascular invasion, and lymph node metastasis. Elevated expression of miR-21 reduced the sensitivity of radio-therapy, and increased recurrence frequency. The diagnostic value of single assay for miR-21 or miR-375 was lower than the combined assay (AUC=0.812 or 0.739 vs. 0.858). They also affected patient prognosis (OR=1.53 or 0.652). MiR-21 and miR-375 presented abnormal expression in Kazak or Uighur esophageal carcinoma patients and were independent factors affecting prognosis. The combined assay of miR-21 and miR-375 may help to make early diagnosis of esophageal cancer.

Entities:  

Keywords:  Esophageal carcinoma; early diagnosis; microRNA-21; microRNA-375; prognosis

Year:  2016        PMID: 27508050      PMCID: PMC4969466     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  26 in total

1.  MicroRNA-340 Inhibits Esophageal Cancer Cell Growth and Invasion by Targeting Phosphoserine Aminotransferase 1.

Authors:  Shuo Yan; Haosheng Jiang; Shiming Fang; Fang Yin; Zhenlei Wang; Yiping Jia; Xianjun Sun; Shaoqiu Wu; Tinghui Jiang; Aiwu Mao
Journal:  Cell Physiol Biochem       Date:  2015-08-27

2.  Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer.

Authors:  Koji Tanaka; Hiroshi Miyata; Makoto Yamasaki; Keijiro Sugimura; Tsuyoshi Takahashi; Yukinori Kurokawa; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  Ann Surg Oncol       Date:  2013-07-10       Impact factor: 5.344

3.  Evaluation of miR-21 and miR-375 as prognostic biomarkers in esophageal cancer.

Authors:  Mette Winther; Jan Alsner; Trine Tramm; Lene Baeksgaard; Eva Holtved; Marianne Nordsmark
Journal:  Acta Oncol       Date:  2015       Impact factor: 4.089

4.  Overregulation of microRNA-212 in the poor prognosis of esophageal cancer patients.

Authors:  B Qi; S G Liu; X G Qin; W J Yao; J G Lu; L Guo; T Y Wang; H C Li; B S Zhao
Journal:  Genet Mol Res       Date:  2014-09-26

5.  Identification of novel molecular targets regulated by tumor suppressive miR-375 induced by histone acetylation in esophageal squamous cell carcinoma.

Authors:  Yuka Isozaki; Isamu Hoshino; Nijiro Nohata; Takashi Kinoshita; Yasunori Akutsu; Naoyuki Hanari; Mikito Mori; Yasuo Yoneyama; Naoki Akanuma; Nobuyoshi Takeshita; Tetsuro Maruyama; Naohiko Seki; Norikazu Nishino; Minoru Yoshida; Hisahiro Matsubara
Journal:  Int J Oncol       Date:  2012-06-28       Impact factor: 5.650

6.  MicroRNA-506 inhibits esophageal cancer cell proliferation via targeting CREB1.

Authors:  Wen-Jian Yao; Yong-Lian Wang; Jian-Guo Lu; Ling Guo; Bo Qi; Zhi-Jun Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  [Diagnostic values of salivary versus and plasma microRNA-21 for early esophageal cancer].

Authors:  Minhua Ye; Penghui Ye; Weizhu Zhang; Jiaqi Rao; Zijun Xie
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2014-06

8.  Serum miR-21 expression in human esophageal squamous cell carcinomas.

Authors:  Er-Hui Cai; Yong-Xin Gao; Zhong-zhi Wei; Wei-Ying Chen; Ping Yu; Ke Li
Journal:  Asian Pac J Cancer Prev       Date:  2012

9.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

10.  Cell-specific detection of miR-375 downregulation for predicting the prognosis of esophageal squamous cell carcinoma by miRNA in situ hybridization.

Authors:  Jiangchao Li; Xiaodong Li; Yan Li; Hong Yang; Lijing Wang; Yanru Qin; Haibo Liu; Li Fu; Xin-Yuan Guan
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

View more
  16 in total

1.  The microRNA-375 as a potentially promising biomarker to predict the prognosis of patients with head and neck or esophageal squamous cell carcinoma: a meta-analysis.

Authors:  Peng Wang; LiangLiang Xu; Lian Li; ShengSheng Ren; JianWei Tang; Ming Zhang; MingQing Xu
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-02-12       Impact factor: 2.503

2.  Erratum: Differential expression of miR-21 and miR-75 in esophageal carcinoma patients and its clinical implication.

Authors:  Guoyu Huang
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

3.  Prognostic alternative splicing signatures and underlying regulatory network in esophageal carcinoma.

Authors:  Zu-Cheng Xie; Hua-Yu Wu; Fu-Chao Ma; Yi-Wu Dang; Zhi-Gang Peng; Hua-Fu Zhou; Gang Chen
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

4.  Estimation of Serum MicroRNA 21 as a Tumour Marker in Carcinoma Oesophagus.

Authors:  Sruthy Harshan; Lancelot Lobo; Suchetha Kumari; Shilpa Shetty
Journal:  Indian J Surg Oncol       Date:  2021-07-08

5.  Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab.

Authors:  Adrien Costantini; Catherine Julie; Coraline Dumenil; Zofia Hélias-Rodzewicz; Julie Tisserand; Jennifer Dumoulin; Violaine Giraud; Sylvie Labrune; Thierry Chinet; Jean-François Emile; Etienne Giroux Leprieur
Journal:  Oncoimmunology       Date:  2018-04-20       Impact factor: 8.110

Review 6.  Non-coding RNAs: new biomarkers and therapeutic targets for esophageal cancer.

Authors:  Xiaobin Hou; Jiaxin Wen; Zhipeng Ren; Guoliang Zhang
Journal:  Oncotarget       Date:  2017-06-27

7.  Downregulation of microRNA-21 inhibited radiation-resistance of esophageal squamous cell carcinoma.

Authors:  Fang Li; Jia-Hua Lv; Long Liang; Jun-Chao Wang; Chu-Rong Li; Lei Sun; Tao Li
Journal:  Cancer Cell Int       Date:  2018-03-20       Impact factor: 5.722

8.  Identification of molecular targets for esophageal carcinoma diagnosis using miRNA-seq and RNA-seq data from The Cancer Genome Atlas: a study of 187 cases.

Authors:  Jiang-Hui Zeng; Dan-Dan Xiong; Yu-Yan Pang; Yu Zhang; Rui-Xue Tang; Dian-Zhong Luo; Gang Chen
Journal:  Oncotarget       Date:  2017-05-30

9.  Machine learning to predict early recurrence after oesophageal cancer surgery.

Authors:  S A Rahman; R C Walker; M A Lloyd; B L Grace; G I van Boxel; B F Kingma; J P Ruurda; R van Hillegersberg; S Harris; S Parsons; S Mercer; E A Griffiths; J R O'Neill; R Turkington; R C Fitzgerald; T J Underwood
Journal:  Br J Surg       Date:  2020-01-30       Impact factor: 6.939

10.  Prognostic Value of MicroRNAs in Esophageal Carcinoma: A Meta-Analysis.

Authors:  Song Gao; Zhi-Ying Zhao; Zhen-Yong Zhang; Yue Zhang; Rong Wu
Journal:  Clin Transl Gastroenterol       Date:  2018-11-13       Impact factor: 4.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.